Please assess the completion status of the following clinical trial:

Trial Title: Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed early adenocarcinoma of the breast~  * Completely excised by surgery with curative intent (R0)~    * Any N OR~   * Any primary tumor greater than 3 cm OR~   * Any primary tumor grade III and greater than 1 cm~ * M0~* No positive supraclavicular nodes~* Hormone receptor status:~  * Estrogen and/or progesterone receptor positive~PATIENT CHARACTERISTICS:~Age:~* Any age~* See Menopausal status~Sex:~* Female~Menopausal status:~* Postmenopausal~  * Any age with bilateral oophorectomy or amenorrhea for at least 5 years OR~ * Age 50 or over:~    * Natural amenorrhea for at least 1 year OR~   * Chemotherapy-induced amenorrhea for at least 2 years OR~   * Radiation-induced amenorrhea (at least 3 months since prior radiotherapy) OR~ * Under age 50:~    * If amenorrheic for less than 5 years (any cause) or prior hysterectomy without bilateral surgical oophorectomy, follicle-stimulating hormone must be assayed to confirm postmenopausal status~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Platelet count greater than 100,000/mm3~* WBC greater than 3,000/mm3~Hepatic:~* SGOT or SGPT less than 2.5 times upper limit of normal (ULN)~Renal:~* Creatinine less than 1.5 times ULN~Cardiovascular:~* No uncontrolled cardiac disease~* No unstable angina~* No congestive heart failure or arrhythmia requiring medical therapy~* No myocardial infarction within the past 3 months~Other:~* No severe osteoporosis~* No other malignancies within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell skin cancer~* No other serious concurrent disease that would preclude study~* No psychiatric disorders that would preclude study~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior neoadjuvant chemotherapy~* No more than 10 weeks since completion of prior adjuvant chemotherapy~Endocrine therapy:~* No prior adjuvant hormonal therapy for breast cancer~* No prior neoadjuvant hormonal therapy (prior to surgery) for duration of more than 4 weeks~* At least 4 weeks since prior hormone replacement therapy~Radiotherapy:~* Not specified~Surgery:~* See Disease Characteristics~* No more than 10 weeks since completion of curative surgery~Other:~* No other concurrent investigational agents or participation in another clinical study (except adjuvant cytotoxic chemotherapy studies)~* Concurrent bisphosphonates allowed

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).